Best Diversified Pharmaceuticals Companies in South Korea
The 69 best Diversified Pharmaceuticals companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Organoid Sciences.
- The Business Research Company
- Data Bridge Market Research
Ranked: Best Diversified Pharmaceuticals companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Organoid Sciences Developer of regenerative medicines for multiple diseases | $39M | 53 mo ago | Public | Jongman Yoo CEO | 2019 | WordPressMySQLPHP+22 | — | — |
| 2 | TiumBio Developer of small molecules therapeutics | $32M | 29 mo ago | Public | Kim Hun-Taek CEO | 2016 | PHPGSAPApache HTTP Server+10 | 60 patents Patents concentrated in chemistry & materials | — |
| 3 | LISCure Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases | $26M | 63 mo ago | Series B | Hwaseop Chin CEO | 2018 | — | — | — |
| 4 | Future Medicine Developer of therapies for treating inflammation, fibrosis, and cancer | $11M | 85 mo ago | Public | Wan Seok Jeong CEO | 2015 | — | 116 patents Patents concentrated in health & consumer products | — |
| 5 | ImmunoBiome Developer of microbiome therapeutics for autoimmunity, cancer, and autism spectrum disorders | $10M | 60 mo ago | Series B | Sin-Hyeog Im CEO | 2019 | — | 33 patents Patents concentrated in health & consumer products | — |
| 6 | Qurient Developing novel small molecule therapeutics against infectious disease and inflammation | — | 26 mo ago | Public | Kiyean Nam Chief Executive Officer | 2008 | GnuboardMySQLPHP+6 | 178 patents Small-molecule CDK7 inhibitors for oncology, antiviral, and anti-inflammatory therapies | — |
| 7 | Enzychem Lifesciences Developer of therapies for treating chemotherapy-induced neutropenia, oral mucositis, and psoriasis | — | 63 mo ago | Public | Ki Sohn CEO | 1999 | — | 264 patents Glycerol-derived immunomodulators and radioprotective agents for mucositis and radiation injury | — |
| 8 | Anterogen Adipose-derived stem cells for therapeutic applications | — | 89 mo ago | Public | — | 2000 | PHPCentOSApache HTTP Server | 110 patents MSC‑hydrogel scaffolds for skin regeneration/wound healing and antiviral prodrug therapies | — |
Top 12 Diversified Pharmaceuticals companies in South Korea
#1
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 51 employees$32Mraised▾
TiumBio has developed small molecules and biomolecules for the treatment of cancer, diabetes & rare diseases. The small molecules portfolio includes NCE401 (ALK5 inhibitor for cancer immunotherapy and IPF in preclinical stage), NCE403 (GnRH antagonist for prostate cancer and endometriosis in Phase 1 stage), NCE406 (Type 2 Diabetes mellitus in preclinical stage). Biopharmaceuticals include NBP604 (Recombinant factor VIIa) for hemophilia is in the preclinical stage, NBP611 (hemophilia) and NBP (hemophilia and rare disease) in the discovery stages.
- Jan 2024Post IPO$12M
- Dec 2023Post IPO$29.9M
- May 2018Series B$21.8M
- 2017Series A$10.2M
#2
Public · Seongnam-si, Gyeonggi-do · founded 2019 · 70 employees$39Mraised▾
Organoid Sciences is a developer of regenerative medicines for multiple diseases. It uses cannabinoid-based technology for the development of a regenerative medicine pipeline.
- Jan 2022Series B$32.5M
- Mar 2020Series A$6.4M
#3
Series B · Seoul, Seoul · founded 2018 · 7 employees$26Mraised▾
Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases. It is used for treating cancer (LB-100 (preclinical), LB-200, LB-300) in the in vivo stage, neurodegenerative diseases (LB-400 (preclinical), LB-500) in the in vivo stage, rheumatoid arthritis (LB-600), and NASH (LB-700). The company has also developed leads for the prevention of hair growth (LB-100f), liver disease (LB-200f), osteoarthritis (LB-300f), and obesity (LB-400f).
- Feb 2021Series B$21M
- Jul 2019Seed$5M
#4
Series B · Pohang, Gyeongsangbuk-do · founded 2019 · 23 employees$10.1Mraised▾
Developer of microbiome therapeutics for autoimmunity, cancer, and autism spectrum disorders
- 2021Series B$10.1M
- 2019Seed—
#5
Public · Seoul, Seoul · founded 2015 · 18 employees$11.4Mraised▾
Future Medicine is developing therapies for treating inflammation, fibrosis, and cancer. They have developed their own nucleoside library platform for developing and reformulating drug candidates. Their molecules have mainly completed the preclinical phase, which are used for treating nonalcoholic fatty liver disease, glaucoma, COPD, and cancer.
- May 2019Series B$6M
- Jul 2018Series A$5.4M
#6
Public · Seongnam-si, Gyeonggi-do · founded 2008 · 31 employees—raised▾
Qurient (formerly known as Quro Science) is a spin-off biotechnology company from institute Pasteur Korea (IPK) dedicated to develop novel therapeutics against infectious disease and inflammation. Qurient has exclusive right to use discovery research products (drug candidates) and resources at IPK including the PhenomicScreen. Simultaneously Qurient is searching for In-Licensing opportunities from external partners such as academia and biotech for aligned strategic indications. The company’s pipelines products include Q203 drug for the treatment of Mycobacterium tuberculosis that is in phase I stage; Q301, a drug candidate for the treatment of atopic dermatitis, which is in phase II development stage; and Q501, an orally available 5-lipoxygenase inhibitor for treatment of asthma that is in late stage of lead optimization development stage. Its pipelines products also comprise Q701, a potent and selective TAM kinase-inhibitor for cancer therapy, which is in preclinical development stage; and CDK7 inhibitor that is non-covalent pico molar biochemical inhibitor that is in lead optimization process.
#7
Public · Seoul, Seoul · founded 1999 · 100 employees—raised▾
Enzychem Lifesciences is developing therapies for treating chemotherapy-induced neutropenia, oral mucositis, and psoriasis. They have developed immune modulation technology. The lead candidate of the company, EC-18, acts as anti-inflammatory and anticancer agents. It is a PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol), a substance naturally duplicated from deer antlers.
#8
Public · Seoul, Seoul · founded 2000 · 43 employees—raised▾
Established a research institute in Boston in 2000, Anterogen began commercializing products using adipose-derived stem cells for the first time in Korea.In January 2012, we obtained a market authorization of Cupistem® injection as an adipose-derived stem cell therapy product for the first time in the world.Anterogen, an emerging global leader in the field of cell therapy products, has developed Adipocell® (for the treatment of depressed scar), Queencell® (for the regeneration of subcutaneous adipose tissue) and Cupistem® injection (for the treatment of Crohn's fistula) with accumulated experiences and R&D technology in stem cell therapy
- Jan 2019Post IPO—
#9
Public · Seongnam-si, Gyeonggi-do · founded 2007 · 25 employees—raised▾
Kainos Medicine develops small molecule therapeutics for cancer, neurological and infectious diseases. It currently has drugs for Parkinson's disease in Phase I trials, a HIV anti-infective and three targeted ant-cancer drugs in pre-clinical testing.
#10
Public · Seongnam-si, Gyeonggi-do · founded 2000—raised▾
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
#11
Series A · Seoul, Seoul · founded 2010 · 19 employees—raised▾
NovMetaPharma is developing new therapeutics drugs for multiple diseases. The company develops drugs and therapeutic agent for Type 2 diabetes, Alzheimer's disease, and obesity. It also provides drugs for immune system improvement and Osteoporosis. NovMetaPharma was formerly known as PNC MetaPharm. The companies lead molecules indicated for type 2 diabetes and obesity are in phase 2a clinical trial, USA. A molecule for Alzheimer’s disease is in phase 1 clinical trial.
- Sep 2015Series A—
#12
Public · Gwangju, Gwangju · founded 2000—raised▾
Peptide API and drug developer for cancer & pain disorders
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.